Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone for Ischemia-Reperfusion Injury in Metabolic Syndrome
NCT00405015Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rosiglitazone in ischemia-reperfusion injury (IRI), sponsored by Radboud University Medical Center. Started Apr 2007; status: completed.
02
Drugs
rosiglitazone
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00405015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405015.